Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
Sermorelin is a synthetic peptide that corresponds to the first 29 amino acids of human growth hormone-releasing hormone (GHRH). An FDA-approved product containing it existed, and Drugs@FDA lists that product's marketing status as discontinued as of our status check on 19 October 2026 [1]. This entry covers the molecule's identity, its proposed mechanism, its regulatory history and the published research record. It follows the standard Peptide Infinity template described in What are peptides? Types, examples and a starter A–Z list.
Status at a glance
Field | Entry |
|---|---|
Name | Sermorelin (sermorelin acetate) |
Other designations | GHRH(1-29)-NH2, GRF(1-29) amide |
Class | Growth hormone-releasing hormone analogue |
Length | 29 amino acids, amidated C-terminus |
U.S. status badge | Approved – discontinued (per Drugs@FDA marketing status at check date) |
FDA record | Drugs@FDA, NDA 019863 (Geref, sermorelin acetate) [1] |
Compounding context | Governed by FDA's section 503A framework; see the FDA pages for current listings [8][9] |
Status checked | 19 October 2026 |
The badge definitions are explained in Peptide FDA status explained: approved to investigational.
Identity and structure
Natural human GHRH is a 44-amino-acid peptide made in the hypothalamus. As general background, early structure–activity work identified the N-terminal portion of the molecule as carrying the activity needed to bind the GHRH receptor. Sermorelin is that N-terminal 29-residue segment, produced synthetically with an amide group at the C-terminal end.
Sermorelin is one member of a larger family of synthetic GHRH-related molecules. Published work in this family includes analogues carrying structural modifications, such as agmatine-containing analogues tested in cattle [5] and lipopeptide GHRH antagonists studied in experimental cancer models [7]. Tesamorelin, another GHRH analogue, is listed in Drugs@FDA under a separate application (022505) [4]. Analytical chemists group synthetic GHRH analogues together as a class when developing detection methods [3].
Proposed mechanism
GHRH analogues act on GHRH receptors found on somatotroph cells in the anterior pituitary gland. Receptor activation signals these cells to synthesise and release growth hormone. Growth hormone in turn drives production of insulin-like growth factor 1 (IGF-1), mainly in the liver.
A central point in the literature concerns where in the hormonal chain a molecule acts. Recombinant growth hormone supplies the end hormone directly. A GHRH analogue acts one step upstream, so the pituitary's own regulatory inputs, including inhibition by somatostatin and feedback from IGF-1, remain in the loop. A 2006 narrative review by Walker and colleagues framed this distinction as a question: whether an upstream, pituitary-stimulating approach might be preferable to direct hormone replacement in adult-onset growth hormone insufficiency [2]. The review presents an argument based on physiology and earlier studies. It is not a randomised comparison, and its title is phrased as a question rather than a conclusion.
Regulatory history
The approved product
Drugs@FDA lists Geref (sermorelin acetate) under new drug application 019863 [1]. The record identifies the application and the product, and at our check date it showed the marketing status as discontinued. Under the Peptide Infinity scheme, this places sermorelin in the "Approved – discontinued" category: an approved product existed, but it is no longer marketed in the United States. Because marketing status can change, readers should confirm it on the live record.
Two points follow from that status:
Discontinued is not the same as withdrawn for safety. A product can leave the market for commercial, manufacturing or other reasons. The Drugs@FDA overview page by itself does not explain why a product was discontinued.
Approval referred to a specific product and use. The historical approval covered one manufactured product for its labelled indications. It did not establish the molecule as approved for any other purpose.
Compounding context
After a branded product leaves the market, questions often arise about pharmacy compounding. The FDA maintains a page on bulk drug substances used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act [8]. It explains the criteria a bulk substance must meet and the categories FDA uses while nominated substances are evaluated. The Pharmacy Compounding Advisory Committee provides public advice to FDA on these questions, and its meeting materials are posted on the FDA's advisory committee pages [9].
Listings on these pages change over time. This entry therefore does not assign sermorelin to a specific 503A category. Readers verifying current status should consult the FDA pages directly [8][9].
The research record
The published literature relevant to sermorelin falls into four groups: reviews of its use in humans, animal studies of GHRH analogues, laboratory research on the wider GHRH system, and anti-doping chemistry.
Human-focused review literature
The Walker et al. review (2006) is the main source in this list that addresses sermorelin and adults directly [2]. It discusses the physiological rationale for a GHRH-based approach and summarises earlier work. As a narrative review, it does not generate new trial data. Its arguments should be read alongside its cited primary studies.
Animal studies of GHRH analogues
GHRH analogues have also been studied in a veterinary context. A 1992 study by Roberge and colleagues evaluated the biological potency of new agmatine-containing GHRH analogues in cattle [5]. Work of this kind shows how small structural changes to the GHRH sequence were tested for altered activity in a bovine model. Findings in cattle do not translate directly to humans.
Laboratory research on the GHRH system
Some GHRH research has little to do with growth hormone release from the pituitary. A 1999 laboratory study by Kiaris and colleagues reported evidence that GHRH can act as an autocrine growth factor in small cell lung carcinoma, meaning the tumour cells may both produce and respond to it [6]. Building on that line of work, Zarandi and colleagues (2006) described lipopeptide GHRH antagonists, molecules designed to block the receptor, with improved antitumour activity in experimental models [7].
These studies concern GHRH and its antagonists in cancer biology, not sermorelin specifically. They are included because they show the GHRH receptor system extends beyond the pituitary. That context matters when weighing any agonist acting on the same receptor.
Anti-doping chemistry
Sermorelin belongs to a class of compounds that sports authorities monitor. Memdouh and colleagues (2021) reviewed advances in detecting synthetic GHRH analogues, the class to which sermorelin belongs [3]. Gajda and colleagues (2019) reported glycine-modified growth hormone secretagogues identified in seized doping material [10]. That finding shows how unapproved variants of GH-axis peptides can appear outside regulated supply chains. A 2026 critical review by Coutinho and colleagues examined the use of peptide and peptide-analogue drugs in recreational and professional sport and bodybuilding [11].
Broader 2026 reviews
Two 2026 reviews survey peptide therapies in adjacent fields. Mendias and colleagues examined the safety and efficacy evidence for approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance [12]. Its framing by approval status is useful for seeing how current literature separates approved products from unapproved ones. Rahman and colleagues reviewed applications, challenges and future directions for therapeutic peptides in orthopaedics [13]. Neither title indicates whether sermorelin or other GHRH analogues are discussed, so both are listed here as context for the wider field, not as evidence about sermorelin.
Evidence summary
Source | Study type | What it reported or examined |
|---|---|---|
Walker et al., 2006 [2] | Narrative review (human focus) | Rationale for a GHRH-based approach in adult-onset GH insufficiency |
Roberge et al., 1992 [5] | Animal (bovine) | Biological potency of agmatine GHRH analogues |
Kiaris et al., 1999 [6] | Laboratory | GHRH as an autocrine growth factor in small cell lung carcinoma |
Zarandi et al., 2006 [7] | Laboratory / experimental | Lipopeptide GHRH antagonists with antitumour activity |
Memdouh et al., 2021 [3] | Analytical review | Detection of synthetic GHRH analogues |
Gajda et al., 2019 [10] | Forensic analysis | Modified GH secretagogues in seized doping material |
Coutinho et al., 2026 [11] | Critical review | Peptide doping in sport and bodybuilding |
What the record does not establish
The sources here do not include a recent, large randomised trial of sermorelin in adults. The adult-focused source is a narrative review [2]. The GHRH oncology studies concern the receptor system and its antagonists, not sermorelin's safety [6][7]. The anti-doping literature documents detection methods and misuse, not clinical outcomes [3][10][11]. A discontinued approval does not establish safety or efficacy for any use beyond its original label. For more on how this site grades evidence and what it does not publish, see About Peptide Infinity.
Frequently asked questions
Is sermorelin FDA approved?
A product containing sermorelin, Geref (sermorelin acetate), was approved under NDA 019863. At our 19 October 2026 check, Drugs@FDA listed its marketing status as discontinued [1]. Peptide Infinity therefore labels sermorelin "Approved – discontinued" rather than "Approved".
How is sermorelin related to tesamorelin?
Both are synthetic analogues of growth hormone-releasing hormone that act on the same pituitary receptor. Sermorelin corresponds to the 29-residue N-terminal fragment of natural GHRH. Tesamorelin is a distinct analogue with its own separate FDA application, 022505 [4].
Why does sermorelin appear in anti-doping research?
GHRH analogues act on the growth hormone axis, so sports authorities monitor them. Analytical chemists have developed methods to detect this class of compounds [3]. Forensic studies have also found modified growth hormone secretagogues in seized material [10].
Further reading: choosing a textbook
Readers who want the underlying physiology in more depth often turn to pharmacology and endocrinology textbooks. A few neutral criteria make comparison easier and make it less likely to pay for an outdated or poorly referenced title.
Edition date: recent editions are more likely to reflect current receptor pharmacology and regulatory history.
Coverage: check the table of contents for the hypothalamic–pituitary axis, hormone feedback loops and receptor signalling.
Referencing: prefer texts that cite primary literature chapter by chapter.
Format and price: compare print, ebook and used copies, and look for transparent pricing across sellers.
Level: introductory texts suit general readers; graduate references assume prior biochemistry.
Textbooks are most useful when read alongside the primary studies they summarise. Checking the publication year against recent regulatory records confirms whether a book is still current.
Last updated: 19 October 2026.
Related on this site
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.